Valemetostat Tosylate
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Trial Timeline
Jun 3, 2021 → Feb 19, 2027
NCT ID
NCT04703192About Valemetostat Tosylate
Valemetostat Tosylate is a phase 2 stage product being developed by Daiichi Sankyo for Relapsed/Refractory Peripheral T-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04703192. Target conditions include Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07303387 | Phase 2 | Recruiting |
| NCT04842877 | Phase 2 | Active |
| NCT04703192 | Phase 2 | Active |
| NCT04102150 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Peripheral T-Cell Lymphoma